Spyre Therapeutics Reports $11.2 Million Net Loss in Q3 2025, Highlights Clinical Advancements

Spyre Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $11.2 million, a significant improvement compared to a net loss of $69.0 million in the same period last year. The company’s total operating expenses increased slightly to $56.9 million from $55.4 million year-over-year, driven primarily by higher research and development costs, which rose to $45.2 million from $44.7 million. General and administrative expenses also saw a 9% increase, totaling $11.6 million, reflecting higher compensation costs associated with an expanded workforce.

In terms of financial position, Spyre's total assets decreased to $504.6 million as of September 30, 2025, down from $608.5 million at the end of 2024. This decline was largely attributed to a reduction in cash and cash equivalents, which fell to $64.9 million from $89.4 million. The company’s liabilities also decreased significantly, from $90.7 million to $49.5 million, primarily due to a reduction in the contingent value rights (CVR) liability, which dropped from $25.1 million to $14.2 million.

Strategically, Spyre has made notable advancements in its clinical pipeline, including the initiation of the SKYLINE Phase 2 platform trial for its product candidates SPY001, SPY002, and SPY003, aimed at treating inflammatory bowel disease (IBD). The company also launched the SKYWAY Phase 2 basket trial for SPY072, targeting rheumatic diseases. These trials are expected to provide critical data on the safety and efficacy of these therapies, with initial results anticipated in 2026.

Operationally, Spyre has focused on expanding its research and development capabilities, resulting in a 91% increase in internal research and development expenses due to a growing headcount. The company has also engaged in significant licensing agreements with Paragon Therapeutics, which have furthered its product development efforts. As of September 30, 2025, Spyre had an accumulated deficit of $1.1 billion, reflecting its ongoing investment in R&D without generating revenue from product sales.

Looking ahead, Spyre anticipates that its existing cash resources will fund operations for at least one year. However, the company acknowledges the need for additional financing to support its research and development activities and to bring its product candidates to market. The management remains optimistic about the potential of its therapeutic pipeline to address unmet medical needs in IBD and rheumatic diseases, while also navigating the challenges posed by market conditions and operational costs.